OBJECTIVE： To observe therapeutic efficacy and safety of oxaliplatin combined with tegafur in the treatment of advanced primary hepatic carcinoma after transcatheter arterial chemoembolization （TACE）. METHODS： 120 patients with advanced primary hepatic carcinoma were selected from our hospital during Apr. 2011-Apr. 2013， and then divided into control group and observation group according to random number table， with 60 cases in each group. Both groups received TACE. Control group was given Oxaliplatin injection 0.08 g/m2 after surgery via catheter arterial puming， within 4 h； observation group was additionally given Tegafur capsules 40 mg/m2，po，bid， on the basis of control group. Both group received treatment for 4 months. Clinical efficacy， hepatic function indexes [ALT， AST， TBIL， DBIL] and alpha-fetoprotein （AFP） level were observed in 2 groups； the occurrence of ADR during treatment was recorded as well as 1-year， 2-year， 3-year follow-up survival rates. RESULTS： Before treatment， there was no statistical significance in hepatic function indexes and AFP （P＞0.05）. After treatment， disease control rate （78.33％） and clinical benefit rate （93.33％） of observation group were significantly higher than those of control group （48.335， 71.67％）， with statistical significance （P＜0.05）. The levels of ALT， AST， TBIL and DBIL in 2 groups were increased significantly， while the observation group was significantly lower than the control group， with statistical significance （P＜0.05）. AFP level of 2 groups were decreased significantly， and the observation group was significantly lower than the control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. 1-year， 2-year， 3-year follow-up survival rates of observation group were significant higher than control group， with statistical significance（P＜0.05）. CONCLUSIONS： Oxaliplatin combined with tegafur is effective for advanced primary hepatic carcinoma after TACE with good safety.